4a7s: Difference between revisions
No edit summary |
No edit summary |
||
(3 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Disease== | ==Structure of human I113T SOD1 mutant complexed with 5-Fluorouridine in the p21 space group== | ||
[[ | <StructureSection load='4a7s' size='340' side='right'caption='[[4a7s]], [[Resolution|resolution]] 1.06Å' scene=''> | ||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4a7s]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4A7S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4A7S FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5UD:5-FLUOROURIDINE'>5UD</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=CU:COPPER+(II)+ION'>CU</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[2wz6|2wz6]], [[1ptz|1ptz]], [[1oez|1oez]], [[1azv|1azv]], [[1hl4|1hl4]], [[2wyz|2wyz]], [[4a7q|4a7q]], [[1ozu|1ozu]], [[2vr6|2vr6]], [[2c9v|2c9v]], [[2wz5|2wz5]], [[2xjl|2xjl]], [[1pu0|1pu0]], [[1fun|1fun]], [[2xjk|2xjk]], [[1sos|1sos]], [[1n19|1n19]], [[1p1v|1p1v]], [[2wz0|2wz0]], [[1l3n|1l3n]], [[2wko|2wko]], [[2af2|2af2]], [[1uxl|1uxl]], [[2vr8|2vr8]], [[1rk7|1rk7]], [[2vr7|2vr7]], [[4sod|4sod]], [[2c9s|2c9s]], [[2v0a|2v0a]], [[1mfm|1mfm]], [[2wyt|2wyt]], [[4a7g|4a7g]], [[1dsw|1dsw]], [[1kmg|1kmg]], [[1ozt|1ozt]], [[1n18|1n18]], [[1ba9|1ba9]], [[2c9u|2c9u]], [[1hl5|1hl5]], [[1spd|1spd]], [[1uxm|1uxm]], [[4a7u|4a7u]], [[4a7t|4a7t]], [[4a7r|4a7r]], [[4a7v|4a7v]]</div></td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Superoxide_dismutase Superoxide dismutase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.15.1.1 1.15.1.1] </span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4a7s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4a7s OCA], [https://pdbe.org/4a7s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4a7s RCSB], [https://www.ebi.ac.uk/pdbsum/4a7s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4a7s ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[[https://www.uniprot.org/uniprot/SODC_HUMAN SODC_HUMAN]] Defects in SOD1 are the cause of amyotrophic lateral sclerosis type 1 (ALS1) [MIM:[https://omim.org/entry/105400 105400]]. ALS1 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms.<ref>PMID:12963370</ref> <ref>PMID:19741096</ref> <ref>PMID:8528216</ref> <ref>PMID:8682505</ref> <ref>PMID:9541385</ref> <ref>PMID:12754496</ref> <ref>PMID:15056757</ref> <ref>PMID:18378676</ref> [:]<ref>PMID:8446170</ref> <ref>PMID:8351519</ref> <ref>PMID:8179602</ref> <ref>PMID:7980516</ref> <ref>PMID:8069312</ref> <ref>PMID:7951252</ref> <ref>PMID:7881433</ref> <ref>PMID:7836951</ref> <ref>PMID:7997024</ref> <ref>PMID:7870076</ref> <ref>PMID:7887412</ref> <ref>PMID:7795609</ref> <ref>PMID:7655468</ref> <ref>PMID:7655469</ref> <ref>PMID:7655471</ref> <ref>PMID:7700376</ref> <ref>PMID:7647793</ref> <ref>PMID:7501156</ref> <ref>PMID:7496169</ref> <ref>PMID:8938700</ref> <ref>PMID:8907321</ref> <ref>PMID:8990014</ref> <ref>PMID:9101297</ref> <ref>PMID:9455977</ref> <ref>PMID:10732812</ref> <ref>PMID:9131652</ref> <ref>PMID:10400992</ref> <ref>PMID:10430435</ref> <ref>PMID:11535232</ref> <ref>PMID:11369193</ref> <ref>PMID:12402272</ref> <ref>PMID:12145308</ref> <ref>PMID:14506936</ref> <ref>PMID:18552350</ref> <ref>PMID:18301754</ref> <ref>PMID:21247266</ref> <ref>PMID:21220647</ref> | |||
== Function == | |||
[[https://www.uniprot.org/uniprot/SODC_HUMAN SODC_HUMAN]] Destroys radicals which are normally produced within the cells and which are toxic to biological systems. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Mutations in the gene encoding Cu/Zn superoxide dismutase-1 cause amyotrophic lateral sclerosis. Superoxide dismutase-1 mutations decrease protein stability and promote aggregation. The mutant monomer is thought to be an intermediate in the pathway from the superoxide dismutase-1 dimer to aggregate. Here we find that the monomeric copper-apo, zinc-holo protein is structurally perturbed and the apo-protein aggregates without reattainment of the monomer-dimer equilibrium. Intervention to stabilize the superoxide dismutase-1 dimer and inhibit aggregation is regarded as a potential therapeutic strategy. We describe protein-ligand interactions for two compounds, Isoproterenol and 5-fluorouridine, highlighted as superoxide dismutase-1 stabilizers. We find both compounds interact with superoxide dismutase-1 at a key region identified at the core of the superoxide dismutase-1 fibrillar aggregates, beta-barrel loop II-strand 3, rather than the proposed dimer interface site. This illustrates the need for direct structural observations when developing compounds for protein-targeted therapeutics. | |||
Ligand binding and aggregation of pathogenic SOD1.,Wright GS, Antonyuk SV, Kershaw NM, Strange RW, Samar Hasnain S Nat Commun. 2013 Apr 23;4:1758. doi: 10.1038/ncomms2750. PMID:23612299<ref>PMID:23612299</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 4a7s" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== | ||
*[[Superoxide | *[[Superoxide dismutase 3D structures|Superoxide dismutase 3D structures]] | ||
== References == | |||
== | <references/> | ||
<references | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Superoxide dismutase]] | [[Category: Superoxide dismutase]] | ||
[[Category: Antonyuk, S V | [[Category: Antonyuk, S V]] | ||
[[Category: Hasnain, S S | [[Category: Hasnain, S S]] | ||
[[Category: Kershaw, N M | [[Category: Kershaw, N M]] | ||
[[Category: ONeil, P M | [[Category: ONeil, P M]] | ||
[[Category: Strange, R W | [[Category: Strange, R W]] | ||
[[Category: Wright, G S.A | [[Category: Wright, G S.A]] | ||
[[Category: Amyotrophic lateral sclerosis]] | [[Category: Amyotrophic lateral sclerosis]] | ||
[[Category: Antioxidant]] | [[Category: Antioxidant]] | ||
[[Category: Oxidoreductase]] | [[Category: Oxidoreductase]] |
Latest revision as of 10:50, 18 August 2022
Structure of human I113T SOD1 mutant complexed with 5-Fluorouridine in the p21 space groupStructure of human I113T SOD1 mutant complexed with 5-Fluorouridine in the p21 space group
Structural highlights
Disease[SODC_HUMAN] Defects in SOD1 are the cause of amyotrophic lateral sclerosis type 1 (ALS1) [MIM:105400]. ALS1 is a familial form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper and lower motor neurons and resulting in fatal paralysis. Sensory abnormalities are absent. Death usually occurs within 2 to 5 years. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of cases leading to familial forms.[1] [2] [3] [4] [5] [6] [7] [8] [:][9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Function[SODC_HUMAN] Destroys radicals which are normally produced within the cells and which are toxic to biological systems. Publication Abstract from PubMedMutations in the gene encoding Cu/Zn superoxide dismutase-1 cause amyotrophic lateral sclerosis. Superoxide dismutase-1 mutations decrease protein stability and promote aggregation. The mutant monomer is thought to be an intermediate in the pathway from the superoxide dismutase-1 dimer to aggregate. Here we find that the monomeric copper-apo, zinc-holo protein is structurally perturbed and the apo-protein aggregates without reattainment of the monomer-dimer equilibrium. Intervention to stabilize the superoxide dismutase-1 dimer and inhibit aggregation is regarded as a potential therapeutic strategy. We describe protein-ligand interactions for two compounds, Isoproterenol and 5-fluorouridine, highlighted as superoxide dismutase-1 stabilizers. We find both compounds interact with superoxide dismutase-1 at a key region identified at the core of the superoxide dismutase-1 fibrillar aggregates, beta-barrel loop II-strand 3, rather than the proposed dimer interface site. This illustrates the need for direct structural observations when developing compounds for protein-targeted therapeutics. Ligand binding and aggregation of pathogenic SOD1.,Wright GS, Antonyuk SV, Kershaw NM, Strange RW, Samar Hasnain S Nat Commun. 2013 Apr 23;4:1758. doi: 10.1038/ncomms2750. PMID:23612299[46] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|